Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07638878 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To determine the optimal objective response rate (ORR) of tislelizumab combined with albumin-bound paclitaxel and platinum agents in patients with KRAS-mutant lung cancer who are ineligible for curative surgery
Trial Details
NCT Number NCT07638878
Lead Sponsor Guangzhou Medical University
Conditions
(from sponsor)		 Lung Cancer (Locally Advanced or Metastatic)
Related terms Lung Neoplasms, Neoplasm Metastasis
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov